CellGenix
| CellGenix GmbH
|
|
|---|---|
 |
|
| legal form | Company with limited liability |
| founding | 1994 |
| Seat |
Freiburg im Breisgau , Germany
|
| management | Felicia M. Rosenthal, Chief Executive Officer (CEO) |
| Number of employees | approx. 50 |
| sales | n / A |
| Branch | Pharmaceutical manufacturer |
| Website | www.CellGenix.com |
| As of May 23, 2020 | |
The CellGenix GmbH is a manufacturer and supplier of reagents for clinical cell therapy and regenerative medicine , in particular growth factors and serum-free media. The company was founded in 1994 and employs around 50 people. The company headquarters are in Freiburg im Breisgau , Germany.
Products and services
In 1995 the company received Europe's first GMP ( Good Manufacturing Practice ) manufacturing license for cell therapeutics, and in 2001 the GMP manufacturing license for a recombinant, patient-specific protein vaccine for patients with non-Hodgkin lymphoma .
The main focus of the company is the development and GMP production of reagents for the ex vivo processing of cells, which are used in research and clinical applications. These include in particular growth factors ( cytokines ) and serum- free media for the expansion and differentiation of various human cells: stem cells (hematopoietic stem and progenitor cells, MSC, iPC, ESC) dendritic cells , NK cells, T cells. The product range includes bag systems for cell culture and cryopreservation of cells.
GMP production of biopharmaceuticals
A patient-specific, recombinant idiotype vaccine (IdioVax) was developed in cooperation with the Freiburg Clinic . The vaccine is used to treat B-cell lymphoma and has completed clinical phase II . A GMP manufacturing license for another recombinant tumor vaccine has been granted.
The cell therapeutic CartiGro is used for autologous chondrocyte transplantation (ACT) to treat damage in the cartilage of the knee joint caused by an accident with the body's own cartilage cells. A serum-free manufacturing process that is currently unique in the world is used to manufacture CartiGro.
CellGenix works on behalf of the Freiburg umbilical cord bank for the GMP processing and storage of allogeneic cord blood stem cells for external donation.
history
The company was founded in 1994 as a spin-off from the Freiburg University Medical Center. The first production license for blood stem cells was issued in 1995 and eight further GMP production processes were approved by 2010, including for dendritic cells, chondrocytes and T cells .
In 1996, Metreon Bioproducts GmbH was founded together with Schering AG , which specializes in cell processing. In 1997 the first serum-free medium for the cultivation and differentiation of dendritic cells was developed and in 2002 the first GMP cytokine, interleukin-4 , was brought onto the market. The product range was expanded to include additional cytokines and various serum-free media. Since 2000 there has been a strategic alliance with the American Fluoro Seal Corporation (Afc) from Gaithersburg , USA, which creates bags for cell culture and cryopreservation, among other things. In 2000 the autologous chondrocyte transplant CartiGro was developed, which is marketed by the Stryker company.
Corporate structure
CellGenix GmbH is a limited liability company (GmbH). The managing director is Professor Dr. Felicia Rosenthal. The company owns the 100% subsidiary Metreon Bioproducts GmbH (head office Freiburg i.Br.), which carries out GMP cell processing. CellGenix holds shares in Afc Inc. in Gaithersburg, USA and CellPrep SA in Buenos Aires , Argentina. In addition to the company's headquarters in Freiburg, there is also a branch in the USA. The products are sold worldwide directly and through distributors.
Web links
- www.CellGenix.com (English)
Individual evidence
- ↑ Management Team , Company Website, accessed May 23, 2020
Coordinates: 48 ° 1 '26.4 " N , 7 ° 50' 8.5" E